Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/22/2020 10/23/2020 10/26/2020 10/27/2020 10/28/2020 Date
7955(c) 7943(c) 8077(c) 8056(c) 7880(c) Last
1 467 484 999 438 1 245 512 1 514 561 1 664 720 Volume
+0.44% -0.15% +1.69% -0.26% -2.18% Change
More quotes
Financials (USD)
Sales 2020 26 659 M - -
Net income 2020 3 027 M - -
Net Debt 2020 13 202 M - -
P/E ratio 2020 47,4x
Yield 2020 2,75%
Sales 2021 30 186 M - -
Net income 2021 4 292 M - -
Net Debt 2021 11 342 M - -
P/E ratio 2021 32,9x
Yield 2021 2,78%
Capitalization 134 B 134 B -
EV / Sales 2020 5,53x
EV / Sales 2021 4,83x
Nbr of Employees 70 600
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - oncology (36.8%); - respiratory diseases (22.9%); - cardiovascular, renal and metabolic diseases (18.6%); - other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases. Net sales are distributed geographically as follows: the United... 
Sector
Pharmaceuticals
Calendar
11/05Earnings Release
More about the company
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
More Ratings
All news about ASTRAZENECA PLC
10/28GSK warns COVID-19 will dent full-year earnings
RE
10/28ASTRAZENECA : Clinical trials to study AstraZeneca's COVID-19 vaccine resume glo..
AQ
10/28ASTRAZENECA : Forxiga cardiovascular outcomes benefit approved in China
AQ
10/28ASTRAZENECA : U.S. strikes deal with Lilly for potential COVID-19 antibody drug
RE
10/28THE UNIVERSITY OF STRATHCLYDE : Construction starts on the Medicines Manufacturi..
AQ
10/28ANALYSIS : Australia's star vaccine maker not immune to virus anxiety
RE
10/28Sanofi, GSK to supply vaccine doses to WHO-backed alliance
RE
10/28Sanofi, GSK to supply vaccine doses to WHO-backed alliance
RE
10/28ASTRAZENECA : Says Forxiga's Cardiovascular Outcomes Benefit Is Approved in Chin..
DJ
10/27Pfizer Says Covid-19 Vaccine Late-Stage Trial Almost Fully Enrolled -- 3rd Up..
DJ
10/27EU warns not enough COVID vaccines for all in Europe until 2022
RE
10/27UK starts real-time review of Moderna's COVID-19 vaccine candidate
RE
10/27Pfizer Says Covid-19 Vaccine Late-Stage Trial Almost Fully Enrolled -- 2nd Up..
DJ
10/27Merck says early data from COVID-19 vaccines expected this year
RE
10/27Novavax delays U.S. trial of COVID-19 vaccine to November
RE
More news
News in other languages on ASTRAZENECA PLC
10/28ASTRAZENECA : examen prioritaire accepté pour Enhertu
10/27CORONAVIRUS : Pfizer n'est pas encore prêt à publier des résultats sur son vacci..
10/27CORONAVIRUS : le point sur la pandémie
10/26A Wall Street, le Dow Jones connaît sa pire séance depuis septembre
10/26LONDON STOCK EXCHANGE : Londres déstabilisée par la flambée des contaminations
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,34 $
Last Close Price 102,36 $
Spread / Highest target 51,9%
Spread / Average Target 15,6%
Spread / Lowest Target -35,5%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC3.59%138 207
JOHNSON & JOHNSON-5.12%376 848
ROCHE HOLDING AG-4.22%283 828
PFIZER INC.-7.96%207 994
MERCK & CO., INC.-16.09%197 256
NOVARTIS AG-19.31%180 257